Premium
Antigen‐specific adaptive immune responses in fingolimod‐treated multiple sclerosis patients
Author(s) -
Mehling Matthias,
Hilbert Patricia,
Fritz Stefanie,
Durovic Bojana,
Eichin Dominik,
Gasser Olivier,
Kuhle Jens,
Klimkait Thomas,
Lindberg Raija L.P.,
Kappos Ludwig,
Hess Christoph
Publication year - 2011
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.22352
Subject(s) - fingolimod , multiple sclerosis , immunology , immune system , medicine , immunity , acquired immune system , blockade , antibody , influenza vaccine , receptor , vaccination
T cells exit secondary lymphoid organs along a sphingosine1‐phosphate (S1P) gradient and, accordingly, are reduced in blood upon fingolimod‐mediated S1P‐receptor (S1PR)‐blockade. Serving as a model of adaptive immunity, we characterized cellular and humoral immune responses to influenza vaccine in fingolimod‐treated patients with multiple sclerosis (MS) and in untreated healthy controls. Although the mode of action of fingolimod might predict reduced immunity, vaccine‐triggered T cells accumulated normally in blood despite efficient S1PR‐blockade. Concentrations of anti–influenza A/B immunoglobulin (Ig)M and IgG also increased similarly in both groups. These results indicate that fingolimod‐treated individuals can mount vaccine‐specific adaptive immune responses comparable to healthy controls. Ann Neurol 2011